Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Brunner TB, Blanck O, Lewitzki V, Abbasi-Senger N, Momm F, Riesterer O, Duma MN, Wachter S, Baus W, Gerum S, Guckenberger M, Gkika E. Brunner TB, et al. Among authors: duma mn. Radiother Oncol. 2019 Mar;132:42-47. doi: 10.1016/j.radonc.2018.11.015. Epub 2018 Dec 20. Radiother Oncol. 2019. PMID: 30825968
Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.
Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F. Guckenberger M, et al. Radiother Oncol. 2016 Mar;118(3):485-91. doi: 10.1016/j.radonc.2015.09.008. Epub 2015 Sep 15. Radiother Oncol. 2016. PMID: 26385265
Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases.
Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Flentje M, Ganswindt U, Hass P, Henkenberens C, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Schmitt V, Semrau S, Sterzing F, Streblow J, Wendt TG, Wittig A, Guckenberger M. Klement RJ, et al. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):841-9. doi: 10.1016/j.ijrobp.2015.12.004. Epub 2015 Dec 15. Int J Radiat Oncol Biol Phys. 2016. PMID: 26972657
Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien R, Lohaus F, Klass ND, Eble MJ, Imhoff D, Kahl H, Petersen C, Gerum S, Henkenberens C, Adebahr S, Hass P, Schrade E, Wendt TG, Hildebrandt G, Andratschke N, Sterzing F, Guckenberger M. Rieber J, et al. Lung Cancer. 2016 Jul;97:51-8. doi: 10.1016/j.lungcan.2016.04.012. Epub 2016 Apr 26. Lung Cancer. 2016. PMID: 27237028
Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease.
Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M. Rieber J, et al. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):511-520. doi: 10.1016/j.ijrobp.2016.09.026. Epub 2016 Sep 26. Int J Radiat Oncol Biol Phys. 2017. PMID: 27843031
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease.
Tanadini-Lang S, Rieber J, Filippi AR, Fode MM, Streblow J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Høyer M, Ricardi U, Sterzing F, Guckenberger M. Tanadini-Lang S, et al. Radiother Oncol. 2017 May;123(2):182-188. doi: 10.1016/j.radonc.2017.01.003. Epub 2017 Feb 4. Radiother Oncol. 2017. PMID: 28169042
Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control.
Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Habermehl D, Hildebrandt G, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Andratschke N. Klement RJ, et al. Radiother Oncol. 2017 May;123(2):227-233. doi: 10.1016/j.radonc.2017.01.013. Epub 2017 Mar 6. Radiother Oncol. 2017. PMID: 28274491
Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.
Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F, Ka Heng Chan M, Ernst I, Krieger T, Duma MN, Oechsner M, Ganswindt U, Heinz C, Alheit H, Blank H, Nestle U, Wiehle R, Kornhuber C, Ostheimer C, Petersen C, Pollul G, Baus W, Altenstein G, Beckers E, Jurianz K, Sterzing F, Kretschmer M, Seegenschmiedt H, Maass T, Droege S, Wolf U, Schoeffler J, Haverkamp U, Eich HT, Guckenberger M. Moustakis C, et al. Among authors: duma mn. Strahlenther Onkol. 2017 Oct;193(10):780-790. doi: 10.1007/s00066-017-1151-8. Epub 2017 May 31. Strahlenther Onkol. 2017. PMID: 28567503 English.
102 results